Multi-target combination of antibiotics as salvage therapy for severe infection caused by pan-resistant Burkholderia cenocepacia following lung transplantation

Q4 Medicine
Nadim Cassir , Benjamin Coiffard , Linda Hadjadj , Julien Bermudez , Liliane Okdah , Lucile Ailhaud , Sophie Alexandra Baron , Martine Reynaud-Gaubert , Xavier Benoit D'Journo , Sami Hraiech , Jean-Marc Rolain
{"title":"Multi-target combination of antibiotics as salvage therapy for severe infection caused by pan-resistant Burkholderia cenocepacia following lung transplantation","authors":"Nadim Cassir ,&nbsp;Benjamin Coiffard ,&nbsp;Linda Hadjadj ,&nbsp;Julien Bermudez ,&nbsp;Liliane Okdah ,&nbsp;Lucile Ailhaud ,&nbsp;Sophie Alexandra Baron ,&nbsp;Martine Reynaud-Gaubert ,&nbsp;Xavier Benoit D'Journo ,&nbsp;Sami Hraiech ,&nbsp;Jean-Marc Rolain","doi":"10.1016/j.tpr.2024.100170","DOIUrl":null,"url":null,"abstract":"<div><div><em>Burkholderia cepacia</em> complex (Bcc) is an important group of opportunistic pathogens most frequently affecting patients with cystic fibrosis and responsible for life-threatening infections. Therapeutic options are limited owing to high levels of resistance of the organism, either intrinsic or acquired, to many antimicrobial agents. We describe here the successful treatment of a patient with cystic fibrosis who developed post-transplant lung abscesses and sternal osteitis caused by pan-resistant <em>Burkholderia cenocepacia.</em> He was treated with a combination of ceftazidime-avibactam, ciprofloxacin, meropenem, minocycline, sulfadiazine, and tobramycin. Repurposing multitarget drugs including old and new antibiotics, and their combinations with synergistic effects is a promising strategy to overcome clinical therapeutic impasses with difficult-to-treat-resistance (DTR) bacteria.</div></div>","PeriodicalId":37786,"journal":{"name":"Transplantation Reports","volume":"10 1","pages":"Article 100170"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451959624000210","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Burkholderia cepacia complex (Bcc) is an important group of opportunistic pathogens most frequently affecting patients with cystic fibrosis and responsible for life-threatening infections. Therapeutic options are limited owing to high levels of resistance of the organism, either intrinsic or acquired, to many antimicrobial agents. We describe here the successful treatment of a patient with cystic fibrosis who developed post-transplant lung abscesses and sternal osteitis caused by pan-resistant Burkholderia cenocepacia. He was treated with a combination of ceftazidime-avibactam, ciprofloxacin, meropenem, minocycline, sulfadiazine, and tobramycin. Repurposing multitarget drugs including old and new antibiotics, and their combinations with synergistic effects is a promising strategy to overcome clinical therapeutic impasses with difficult-to-treat-resistance (DTR) bacteria.
多靶点联合抗生素抢救治疗肺移植术后广泛耐药结核杆菌严重感染
洋葱伯克霍尔德菌复合体(Bcc)是一组重要的机会性病原体,最常影响囊性纤维化患者,并导致危及生命的感染。由于该生物体对许多抗微生物药物具有高水平的内在或获得性耐药性,因此治疗选择有限。我们在这里描述了一例囊性纤维化患者的成功治疗,该患者在移植后出现肺脓肿和胸骨骨炎,这是由泛耐药伯克霍尔德菌引起的。给予头孢他啶-阿维巴坦、环丙沙星、美罗培南、米诺环素、磺胺嘧啶和妥布霉素联合治疗。包括新旧抗生素在内的多靶点药物的再利用及其协同作用是克服难治性耐药(DTR)细菌的临床治疗僵局的一种有希望的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Transplantation Reports
Transplantation Reports Medicine-Transplantation
CiteScore
0.60
自引率
0.00%
发文量
24
审稿时长
101 days
期刊介绍: To provide to national and regional audiences experiences unique to them or confirming of broader concepts originating in large controlled trials. All aspects of organ, tissue and cell transplantation clinically and experimentally. Transplantation Reports will provide in-depth representation of emerging preclinical, impactful and clinical experiences. -Original basic or clinical science articles that represent initial limited experiences as preliminary reports. -Clinical trials of therapies previously well documented in large trials but now tested in limited, special, ethnic or clinically unique patient populations. -Case studies that confirm prior reports but have occurred in patients displaying unique clinical characteristics such as ethnicities or rarely associated co-morbidities. Transplantation Reports offers these benefits: -Fast and fair peer review -Rapid, article-based publication -Unrivalled visibility and exposure for your research -Immediate, free and permanent access to your paper on Science Direct -Immediately citable using the article DOI
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信